Table 1. . Baseline characteristics of patients with epithelial ovarian cancer (n = 91).
| Characteristics | n (%) |
|---|---|
| Mean age (±SD) in years | 47.6 ± 14.0 |
| Mean BMI (±SD) in kg/m2 | 23.6 ± 5.1 |
| Median serum CA-125 levels (IQR) in U/ml | 113.6 (48.8, 597.0) |
| Median SII (IQR) | 576.4 (295.6, 1218.7) |
| Parity | |
| Nulliparous | 41 (45.1) |
| Multiparous | 50 (54.9) |
| Menopausal status | |
| Premenopause | 51 (56.0) |
| Postmenopause | 40 (44.0) |
| Comorbidity | |
| Yes | 16 (17.6) |
| No | 75 (82.4) |
| Upfront primary treatment | |
| PDS | 57 (62.6) |
| NACT and IDS | 34 (37.4) |
| Ascites | |
| Yes | 36 (39.6) |
| No | 55 (60.4) |
| FIGO stage | |
| Early (I and II) | 28 (30.8) |
| Advanced (III and IV) | 63 (69.2) |
| Residual disease status | |
| Optimal (R0/R1) | 39 (42.9) |
| Suboptimal (R2) | 52 (57.1) |
| Histologic subtype | |
| Type I (LGSC and others) | 32 (35.2) |
| Type II (HGSC) | 59 (64.8) |
CA: Cancer antigen; FIGO: International Federation of Gynecology and Obstetrics; HGSC: High-grade serous carcinoma; IDS: Interval debulking surgery; IQR: Interquartile range; LGSC: Low-grade serous carcinoma; NACT: Neoadjuvant chemotherapy; PDS: Primary debulking surgery; SD: Standard deviation; SII: Systemic immune-inflammation index.